NCT02267512View on ClinicalTrials.gov

Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
De Novo Kidney Transplant Patients
Interventions
DRUG

ATG-F

Intravenous (IV)

Trial Locations (14)

Unknown

Beijing

Changchun

Chengdu

Guangzhou

Hangzhou

Jinan

Nanjing

Shanghai

Shenyang

Tianjin

Wenzhou

Wuhan

Xi'an

Zhengzhou

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY